12 Recruiting Hematological Malignancies Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for Hematological Malignancies
Top Recruiting Hematological Malignancies Studies
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
📍 University of Alabama Birmingham — Birmingham, Alabama
View Study & Checklist ➔ 🔵 Active, Not Recruiting Observational / Diagnostic 📋 Clinical Research Protocol
Feasibility of the Use of Weighted Blankets to Improve Sleep Among Patients With Hematological Malignancies
📍 The University of Texas MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
📍 City of Hope — Duarte, California
View Study & Checklist ➔ 🟡 Not Yet Recruiting Phase2 💊 Investigational Drug / Biologic
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
📍 The University of Texas M. D. Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
📍 University of Alabama Birmingham — Birmingham, Alabama
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
📍 Memorial Sloan Kettering Cancer Center (MSKCC) — New York, New York
View Study & Checklist ➔ 🟢 Recruiting Phase3 📋 Clinical Research Protocol
Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
📍 Tufts Medical Center — Boston, Massachusetts
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
📍 Research Site — New York, New York
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
📍 University of Nebraska Medical Center — Omaha, Nebraska
View Study & Checklist ➔